Immunomedics Announces Encouraging Preclinical Study Data, Shares Give Up Early Morning Gains

Immunomedics, Inc. IMMU, a clinical stage biopharmaceutical company that focuses on the treatment of cancer, presented data at the 2016 American Association for Cancer Research's annual meeting.

Immunomedics said in a corresponding press release that its presentation focused on the results of a Phase 1 study. Specifically, the company's IMMU-114 was shown to be superior to anti-CD20 therapy using rituximab. In addition, IMMU-114 also achieved a significant survival benefit in an animal model of human acute lymphoblastic leukemia (ALL) that is refractory to doxorubicin.

"These data demonstrate IMMU-114's overall activity in diverse hematopoietic cancers and provide the rationale for continued clinical and preclinical evaluation alone and combined with current chemotherapeutic agents that are active in their respective indications," commented Cynthia L. Sullivan, President and Chief Executive Officer.

In a separate presentation, Immunomedics provided preclinical data for sacituzumab govitecan, the company's lead antibody-drug conjugate (ADC) for solid cancer therapy. The drug showed a "synergistic effect" when combined with olaparib, a polymerase inhibitor, as well as additive therapeutic results with microtubule inhibitors.

Despite the encouraging data, shares of Immunomedics were trading nearly flat at $2.86 early Monday afternoon. After opening for trading at $2.95, shares quickly rose to $3.00 but then gave up most of gains.

Posted In: NewsMoversBiopharmaceutical CompaniesCynthia SullivanIMMU-114ImmunomedicsSacituzumab Govitecan
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...